Fundraising Fox

Cytonics

Jupiter, US · Florida corporation

cytonics.com ↗

Cytonics develops A2M-based biologic therapies for osteoarthritis, including its lead candidate CYT-108, a "super A2M" drug in FDA clinical trials that targets enzymes responsible for cartilage degradation. The company aims to create the first disease-modifying therapy for osteoarthritis rather than treating only symptoms.

BiotechLongevityMedical Devices

Founders & leadership

JBJoey Bose
Joey BosePresident

Reported raises · per SEC filings

Form D private placements

$839K disclosed across 3 rounds · 2018–2019

▶$20KraisedJun 2019 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$450K
Amount sold
$20K
Minimum investment
$20K
Sales commissions
$1.5K
Placement agents
SI Securities, LLC
First sale
Jun 2019
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$25KraisedJun 2019 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$450K
Amount sold
$25K
Minimum investment
$20K
Sales commissions
$1.9K
Placement agents
SI Securities, LLC
First sale
Apr 2019
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$794KraisedDec 2018 · 20 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$1M
Amount sold
$794K
Minimum investment
$25K
First sale
Jun 2018
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Cytokinetics30 shared keywordsCytokinetics is a biopharmaceutical company focused on muscle biology, developing small molecule muscle activators and inhibitors to treat diseases involving compromised muscle function, including heart failure, hypertrophic cardiomyopathy, and neuromuscular diseases.
Tectonictx17 shared keywordsTectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
CytomX15 shared keywordsCytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
Cytonus Therapeutics15 shared keywords

Companies competing with Cytonics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2011$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$192.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Cytonics do?
Cytonics develops A2M-based biologic therapies for osteoarthritis, including its lead candidate CYT-108, a "super A2M" drug in FDA clinical trials that targets enzymes responsible for cartilage degradation. The company aims to create the first disease-modifying therapy for osteoarthritis rather than treating only symptoms.
How much funding has Cytonics raised?
Cytonics has disclosed $839K raised across 3 rounds.
Where is Cytonics headquartered?
Cytonics is headquartered in Jupiter, US.